Du är här


Bavarian Nordic A/S: Bavarian Nordic Receives Contract Valued at USD 9 Million from Janssen as part of Advanced Development of Prime-Boost Ebola Vaccine Regime

* Total options and awards could amount up to USD 33 million

COPENHAGEN, Denmark, September 14, 2015
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the award of a
subcontract from Crucell Holland B.V., one of Janssen Pharmaceutical
Companies of Johnson&Johnson, valued at USD 9 million. This is part of a
contract awarded to Janssen by the U.S. Biomedical Advanced Research and
Development Authority (BARDA) to support the advanced development and
manufacturing of the Ebola prime-boost vaccine regimen which consists of
Bavarian Nordic's MVA-BN®Filo and Ad26.ZEBOV from Janssen.

The five-year base subcontract covers studies to improve the manufacturing
process and establish long-term storage of MVA-BN Filo bulk vaccine. The
contract also includes options for an additional USD 24 million to implement
process development activities for formulation of a final drug product with a
longer shelf life.

As part of an accelerated development program, Janssen has initiated multiple
clinical studies of the prime-boost Ebola vaccine regimen in Europe and
Africa. By awarding a contract to Janssen, BARDA is prioritizing the rapid
development of this promising vaccine regimen candidate. To date, Bavarian
Nordic has produced and delivered the bulk equivalent of over one million
doses of its vaccine.

Paul Chaplin, President&Chief Executive Officer of Bavarian Nordic, said: "We
are very pleased to strengthen our collaboration with Janssen on the
accelerated development of the prime-boost Ebola vaccine regimen. More
importantly, it is encouraging that the U.S. Government - through BARDA, with
whom we have worked for over a decade - recognizes the potential of this
vaccine to build international preparedness for current and future Ebola

As the majority of revenue from the contract will be recognized in 2016 and
2017, no changes are made in the Company's expectations for the financial
results for 2015.


Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271

Federal funding acknowledgments

The Janssen project has been funded in part with Federal funds from the Office
of the Assistant Secretary for Preparedness and Response, Biomedical Advanced
Research and Development Authority, Department of Health and Human Services,
under Contract No. HHSO100201500008C.

About MVA-BN Filo

MVA-BN Filo is a multivalent vaccine candidate designed to protect against
Ebola, Sudan and Marburg viruses. The vaccine candidate was originally
developed in collaboration with the National Institute of Allergy and
Infectious Diseases, part of the National Institutes of Health (NIH).

In October 2014, Bavarian Nordic and Janssen entered into a global license and
a supply agreement for the MVA-BN Filo vaccine. This was part of an overall
commitment made by Johnson&Johnson to accelerate and significantly expand the
production of the preventative Ebola vaccine program.

Preclinical studies conducted by the NIH of a prime-boost vaccination regimen
consisting of MVA-BN Filo and Janssen's Ad26.ZEBOV vaccine resulted in
complete protection from death due to the Ebola virus, which is the cause of
the current epidemic in West Africa.

About Bavarian Nordic

Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian
Nordic has developed a portfolio of biological countermeasures, including the
non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for
emergency use by the U.S. and other governments. The vaccine is approved in
the EU (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are pioneering the development of an Ebola vaccine regimen,
which has been fast-tracked by authorities in response to the current
situation in West Africa. Additionally, in collaboration with the National
Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies based on its versatile pox-virus based technologies,
including PROSTVAC®, which is currently in Phase 3 clinical development for
the treatment of advanced prostate cancer. The company has partnered with
Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For
more information visitwww.bavarian-nordic.comor follow us on

Forward-looking statements

This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.